AL-S Pharma Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 3

AL-S Pharma General Information

Description

Developer of antibody therapeutics designed to slow disease progression in amyotrophic lateral sclerosis by targeting misfolded SOD1. The company offers a recombinant human antibody that selectively depletes toxic misfolded SOD1 while preserving normal protein function, enabling patients with ALS to reduce disease-driving mechanisms and improve clinical outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Care of Neurimmune AG
  • Wagistrasse 18, Schlieren
  • 8952 Zurich
  • Switzerland
+41 044
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • Care of Neurimmune AG
  • Wagistrasse 18, Schlieren
  • 8952 Zurich
  • Switzerland
+41 044

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AL-S Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 30-Jan-2018 Completed Product Development
2. Early Stage VC 07-Dec-2016 Completed Product Development
1. University Spin-Out 01-Jan-2016 Completed Startup
To view AL-S Pharma’s complete valuation and funding history, request access »

AL-S Pharma Patents

AL-S Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024262641-A1 In vivo imaging of an als biomarker and means therefor Pending 24-Apr-2023
AU-2024262641-A9 In vivo imaging of an als biomarker and means therefor Pending 24-Apr-2023
EP-4454666-A1 In vivo imaging of an als biomarker and means therefor Pending 24-Apr-2023
EP-4702057-A1 In vivo imaging of an als biomarker and means therefor Pending 24-Apr-2023
US-20260306683-A1 In vivo imaging of an als biomarker and means therefor Pending 24-Apr-2023 A61K51/1096
To view AL-S Pharma’s complete patent history, request access »

AL-S Pharma Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Neurimmune Corporation Minority
TVM Capital Life Science Venture Capital Minority
University of Zürich University
To view AL-S Pharma’s complete investors history, request access »

AL-S Pharma FAQs

  • When was AL-S Pharma founded?

    AL-S Pharma was founded in 2016.

  • Where is AL-S Pharma headquartered?

    AL-S Pharma is headquartered in Zurich, Switzerland.

  • What industry is AL-S Pharma in?

    AL-S Pharma’s primary industry is Drug Discovery.

  • Is AL-S Pharma a private or public company?

    AL-S Pharma is a Private company.

  • What is AL-S Pharma’s current revenue?

    The current revenue for AL-S Pharma is .

  • Who are AL-S Pharma’s investors?

    Neurimmune, TVM Capital Life Science, and University of Zürich have invested in AL-S Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process